Reading NUTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUTX free→Reading NUTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track NUTX free→NASDAQHealth CareMedical Care FacilitiesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, but management's recent track record has been unsteady, with frequent disruptive corporate changes. Earnings quality is robust, cash backs up reported profits, while risk is high and the sector backdrop is a headwind. Peer multiples imply a price about 52% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. Key factors to watch include guidance changes from NUTX and performance trends from sector bellwethers like HCA, THC, and DVA. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 7 valuation methods, at three horizons. Current price $144.40. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $144 NUTX trades at 7× p/e, below its 14× p/e peer median. Our $294 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 51% below a flat-multiple fair value, below our forecast of about 15%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 2.83x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $2.87 → $4.88 (+69.9% / 30d). 2 raised, 0 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 79.1% above current price.
Market and fundamentals agree. Analysts are positioned bullishly on a fundamentally strong name.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$281.
How much price usually moves either way.
On a bad day, this stock has moved -$906.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $5,432.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Comparing Nutex to peers like Lilly and AbbVie can show if Nutex is gaining or losing ground. This helps investors understand its market position.
Confirms one read:Nutex's score is now above 21. This is better than its peers.
Confirms the other:Nutex's composite insight score drops below 19, lagging peers.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for NUTX yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be s…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q1, 2025-Q2, 2025-Q3, 2026-Q1
A side-by-side read on sector standing, valuation, and risk versus Health Care Facilities.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
NUTX Nutex Health, Inc. | Above typical Show detailsSector percentile: 89 of 100 | inexpensive | high |
HCA HCA Healthcare | Above typical Show detailsSector percentile: 81 of 100 | fair | moderate |
THC Tenet Health | Above typical Show detailsSector percentile: 87 of 100 | fair | elevated |
EHC Encompass Health | Above typical Show detailsSector percentile: 97 of 100 | full | moderate |
UHS Universal Health Services | Above typical Show detailsSector percentile: 93 of 100 | inexpensive | elevated |
9 material management or governance events in the past 24 months, led by legal/regulatory items. Historically, Health Care names rated volatile grew net income 43% of the time over the next year (vs 57% for the rest of the cohort, n=600).
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
Met or beat guidance 0% of the last 1 guided quarters · -23.1% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Management aims to achieve a diluted EPS of $6.52 for the fiscal year 2026.
Newly stated in 2026-Q1. Management has set a guidance of $6.52 EPS for the fiscal year 2026. The financials show a diluted EPS of 6.52 for 2026-Q1, indicating alignment with the annual target. The trajectory is delivering as per the guidance.
“Guidance: 'diluted EPS of $6.52 per share for 2026.'”
Continue to build on the record revenue growth achieved in previous years.
Stated in 1 of last 1 quarters. Revenue grew from $151.679M in 2025-Q4 to $216.485M in 2026-Q1, showing a strong growth trajectory. Management's focus on sustaining revenue growth is delivering as evidenced by the financials.
“We are continuing to add to a record year with 225% revenue growth.”
Focus on increasing operating income through strategic initiatives.
Newly stated in 2026-Q1. Operating income rose from $30.918M in 2025-Q4 to $81.265M in 2026-Q1, indicating a successful focus on increasing operating income. The trajectory is delivering as per management's strategic initiatives.
“Operating income increased significantly over the quarters.”
Why it matters: If health care sector revenue growth speeds up, it may boost Nutex's performance. This could signal a better environment for growth.
Confirms:Health care sector revenue growth rises back toward 10% year over year.
Disproves:Health care sector revenue growth remains below 5% year over year.
Why it matters: Earnings results will show how well Nutex is managing in a tough sector. Investors will gauge growth and profitability.
Confirms one read:Earnings report shows revenue growth above 10% year over year.
Confirms the other:Earnings report shows revenue growth below 5% year over year.
OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be si…
OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be si…
OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be si…
OF THIS CURRENT REPORT, INCLUDING EXHIBIT 99.1 ATTACHED HERETO, SHALL NOT BE DEEMED “FILED” FOR THE PURPOSES OF SECTION 18 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED, NOR SHALL IT BE DEEMED INCORPORATED BY REFERENCE INTO ANY REGISTRATION STATEMENT OR OTHER FILING PURSUANT TO THE SECURITIES ACT OF 1933, AS AMENDED, EXCEPT AS OTHERWISE EXPRESSLY STATED IN SUCH FILING SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be si…